Skip to content
Study details
Enrolling now

Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance

SF Research Institute, Inc.
NCT IDNCT07220694ClinicalTrials.gov data as of Apr 2026
Target enrollment

140

Study length

about 28 days

Ages

40–80

Locations

1 site in CA

About this study

This trial is testing if a supplement called Sabroxy® can improve insulin resistance and thinking skills in adults with mild cognitive impairment and insulin resistance. Participants will take either Sabroxy® or a placebo for 8 weeks, and researchers will measure changes in insulin resistance, thinking skills, and other markers of health.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Sabroxy®

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low13%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Secondary: Change in Inflammatory Biomarker (High-Sensitivity C-Reactive Protein, hs-CRP), Change in Montreal Cognitive Assessment (MoCA) Total Score

Body systems

Neurology